Seung Suh Hong
Director/Board Member at OCULAR THERAPEUTIX, INC.
Net worth: 37 519 $ as of 29/04/2024
Seung Suh Hong active positions
| Companies | Position | Start | End |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC. | Director/Board Member | 10/06/2019 | - |
| Independent Dir/Board Member | 10/06/2019 | - | |
Cellemedy Co., Ltd.
 Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Chief Operating Officer | 31/12/2020 | - |
| President | 31/12/2020 | - | |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Director/Board Member | 31/12/2020 | - |
| Novelgen Co. Ltd(South Korea) | Director/Board Member | 31/03/2020 | - |
Career history of Seung Suh Hong
Former positions of Seung Suh Hong
| Companies | Position | Start | End |
|---|---|---|---|
| Celltrion Healthcare Japan KK | President | 31/12/2015 | 01/01/2019 |
| CELLTRION HEALTHCARE CO., LTD. | Chief Executive Officer | 31/10/2014 | 30/11/2015 |
| Corporate Officer/Principal | 31/03/2002 | 31/10/2014 | |
| President | 31/10/2014 | 30/11/2015 |
Training of Seung Suh Hong
| Seoul National University | Doctorate Degree |
Statistics
International
| South Korea | 5 |
| United States | 2 |
| Japan | 2 |
Operational
| Director/Board Member | 3 |
| President | 3 |
| Independent Dir/Board Member | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| CELLTRION HEALTHCARE CO., LTD. | Health Technology |
| Private companies | 4 |
|---|---|
| Celltrion Healthcare Japan KK | |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
Cellemedy Co., Ltd.
Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Commercial Services |
| Novelgen Co. Ltd(South Korea) |
- Stock Market
- Insiders
- Seung Suh Hong
- Experience
